Increased Urine IgM and IgG₂ Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes

Table 1

Baseline characteristics of 54 patients randomized to dalteparin or placebo.

	All	Dalteparin	Placebo
	𝑁=54	𝑁=28	𝑁=26
Age (years)	75 (54–90)	73 (57–86)	75 (54–90)
Gender (male/female)	37/17	17/11	20/6
Smoker/ex-smoker/nonsmoker (𝑛)	9/14/31	4/3/21*	5/11/10
HbA1c (%)	6.7 (5.0–11.0)	6.9 (5.1–11)	6.9 (5.0–9.6)
Diabetes duration (years)	17 ± 9	17 ± 10	16 ± 8
Tablets/insulin/tablets + insulin/diet (𝑛)	10/31/8/5	4/18/3/3	6/13/5/2
Antihypertensive treatment (𝑛) (ACE/β/Ca/diuretic/other)	10/13/5/22/4	5/6/3/14/0	5/7/2/8/4
Systolic blood pressure (mmHg)	158 ± 22	160 ± 22	155 ± 22
Diastolic blood pressure (mmHg)	80 ± 11	78 ± 9	82 ± 12
P-Creatinine (μmol/L)	83 (53–160)	83 (57–130)	84 (53–160)
GFR (mL/min)	74 (17–218)	74 (34–190); (𝑛=22)	80 (17–218); (𝑛=22)
Albuminuria (normo/micro/macro):
Baseline (𝑛)	33/15/6	18/8/2	15/7/4
At endpoint (𝑛)	35/12/7	18/7/3	17/5/4

* 𝑃<0.05 versus placebo. Data are given as mean ± SD, or as median and minimum-maximum values. GFR: glomerular filtration rate: creatinine clearance.